{"id":"W2005692436","doi":"10.1158/0008-5472.sabcs13-s5-04","title":"Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical endpoint; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Taxane; Placebo; Interim analysis; Phases of clinical research; Progression-free survival; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004014499,0.002188439,0.003288763,0.0005293314,0.0005610732,0.001488752,0.001119899,0.00188497,0.02295632],"category_scores_gemma":[0.003205195,0.0006410842,0.002527443,0.0005084554,0.001283703,0.0009867318,0.0003506889,0.00402244,0.002930639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008578284,"about_ca_system_score_gemma":0.0019558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007131151,"about_ca_topic_score_gemma":0.001753057,"domain_scores_codex":[0.9984496,0.00100534,0.0001048802,0.0001947617,0.0001203692,0.0001250877],"domain_scores_gemma":[0.9981732,0.0004974101,0.0004966711,0.0001225509,0.0001918075,0.0005183283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.973114,0.003423315,0.0004075577,0.001649816,0.001424927,0.00004631126,0.00002719908,0.0002279998,0.00214949,0.0001890636,0.005199357,0.01214115],"study_design_scores_gemma":[0.9648334,0.03091763,0.001093754,0.0000981915,0.0008496838,0.00003064519,0.000008490584,0.0002252937,0.0004711075,0.0001457807,0.00131639,0.000009742388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8592268,0.0357151,0.003454001,0.006610961,0.003126208,0.03480175,0.0271202,0.001339187,0.0286058],"genre_scores_gemma":[0.9343677,0.00916543,0.005044776,0.005253034,0.001755592,0.01546043,0.01204442,0.0001703876,0.0167383],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02295632,"threshold_uncertainty_score":0.07679653,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09301979136539842,"score_gpt":0.4564439374470701,"score_spread":0.3634241460816717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}